Broad Clinical-Stage Immunotherapy Platforms
Activators

Activated
NK & T Cell
Immuno-Modulators

Activated M1
Macrophages
Vaccines

Memory
T Cells
We established ImmunityBio to advance the next generation of immunotherapies and to address serious unmet needs within oncology and infectious diseases. Our platform is designed to overcome limitations of the existing therapeutic paradigm based on T cell-based immunotherapies, such as checkpoint inhibitors and chimeric antigen receptor T cells, or CAR-T cells.
Fundamentally, our platform promotes innate and adaptive immune responses by activating cytokines, natural killer, or NK, cells, T cells and tumoricidal macrophages, and seeks to establish “immunological memory” to support longer-term protection against disease. We believe our novel approach significantly improves upon standard immunotherapies to induce more rapid, robust and durable clinical benefit.
Our Clinical Stage Platforms
(1) Antibody fusion proteins which activate NK, T, and memory T cells;
(2) Albumin-based tumor microenvironment immune modulators; and
(3) Second generation adenovirus (hAd5) and yeast vectors to activate dendritic cells and induce long-term T cell memory.

Anktiva (N-803)
fast track &
breakthrough designation

Aldoxorubicin

Adenovirus
Recent News
ImmunityBio Simulations Reveal Why the New Strain of SARS-CoV-2 in South Africa is Spreading Fast and May ‘Escape’ Existing Immunity
Using Molecular Dynamic (MD) simulation, ImmunityBio scientists assessed the affinity of mutated spike receptor binding domain (RBD) of SARS-CoV-2 to its receptor on human cells, ACE2 The mutations...
ImmunityBio Announces Phase I Trial of COVID-19 Vaccine Candidate in South Africa as New Variants of SARS-CoV-2 Spread
Plans to study COVID-19 subcutaneous and oral, room-temperature capsule vaccineto protect against escape mutants ImmunityBio to conduct initial trial of its human adenovirus (hAd5) COVID-19 vaccine...
NantKwest, ImmunityBio Announce Positive Interim Data on Survival Rates in Metastatic Pancreatic Cancer Trials
Pivotal QUILT 88 trial based on combination immunotherapy of “Cancer Moonshot” strategy; early indications of increased survival rate for pancreatic cancer patients with no other approved treatment...